- Home
- REFR vs OMGA Comparison
REFR vs OMGA Comparison
Compare REFR & OMGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- OMGA
- Stock Information
- Founded
- REFR 1965
- OMGA 2017
- Country
- REFR United States
- OMGA United States
- Employees
- REFR N/A
- OMGA N/A
- Industry
- REFR Multi-Sector Companies
- OMGA Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- OMGA Health Care
- Exchange
- REFR Nasdaq
- OMGA Nasdaq
- Market Cap
- REFR 67.4M
- OMGA 74.5M
- IPO Year
- REFR N/A
- OMGA 2021
- Fundamental
- Price
- REFR $1.97
- OMGA $0.82
- Analyst Decision
- REFR
- OMGA Strong Buy
- Analyst Count
- REFR 0
- OMGA 5
- Target Price
- REFR N/A
- OMGA $9.20
- AVG Volume (30 Days)
- REFR 27.0K
- OMGA 450.6K
- Earning Date
- REFR 11-07-2024
- OMGA 11-14-2024
- Dividend Yield
- REFR N/A
- OMGA N/A
- EPS Growth
- REFR N/A
- OMGA N/A
- EPS
- REFR N/A
- OMGA N/A
- Revenue
- REFR $1,469,616.00
- OMGA $8,095,000.00
- Revenue This Year
- REFR N/A
- OMGA $127.25
- Revenue Next Year
- REFR N/A
- OMGA N/A
- P/E Ratio
- REFR N/A
- OMGA N/A
- Revenue Growth
- REFR 102.07
- OMGA 185.04
- 52 Week Low
- REFR $0.90
- OMGA $0.77
- 52 Week High
- REFR $2.41
- OMGA $6.30
- Technical
- Relative Strength Index (RSI)
- REFR 40.92
- OMGA 36.06
- Support Level
- REFR $1.92
- OMGA $1.06
- Resistance Level
- REFR $2.31
- OMGA $1.17
- Average True Range (ATR)
- REFR 0.11
- OMGA 0.11
- MACD
- REFR -0.02
- OMGA -0.02
- Stochastic Oscillator
- REFR 12.82
- OMGA 2.25
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. Its revenue source comes from the licensing of technology.
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.